DelveInsight’s “Graves Ophthalmopathy Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Graves Ophthalmopathy, historical and forecasted epidemiology as well as the Graves Ophthalmopathy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the Graves Ophthalmopathy Market with DelveInsight's In-Depth Report @ Graves Ophthalmopathy Market Size
Key Takeaways from the Graves Ophthalmopathy Market
- In November 2024:- Viridian Therapeutics- This is a randomized (meaning participants will be assigned to study arms by chance), double-masked (meaning study doctor and participant will not know which study arm participant is assigned to), placebo-controlled study that will include participants with chronic TED. The key objectives of this study are to determine if VRDN-003 is efficacious, safe and tolerable when administered as subcutaneous/SC injections every 4 weeks or every 8 weeks compared to placebo in participants with chronic TED.
- In November 2024:- Amgen- The main objective of the study is to evaluate the effect of teprotumumab subcutaneous administration versus placebo on the proptosis responder rate (ie, the percentage of participants with a ≥ 2-mm reduction from Baseline in the study eye without deterioration [≥ 2-mm increase] of proptosis in the fellow eye) at Week 24. The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
- In November 2024:- ACELYRIN Inc.- A Phase 1/2, Adaptive, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of Lonigutamab in Subjects with Thyroid Eye Disease (TED). Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.
- Among the 7MM, the United States accounted for the highest Graves’ ophthalmopathy market size in 2023, followed by Germany.
- During the forecast period (2024–2034), pipeline candidates such as batoclimab and VRDN-001 are expected to drive the rise in the Graves’ Ophthalmopathy market size.
- By 2034, TEPEZZA is expected to garner the highest Graves’ ophthalmopathy market share in the 7MM.
- The leading Graves Ophthalmopathy Companies such as Immunovant Sciences, Novartis, Viridian Therapeutics, and others.
- Promising Graves Ophthalmopathy Therapies such as Batoclimab (IMVT 1401), RVT-1401, Teprotumumab, VRDN-001 10 mg/kg Drug, TOUR006 - 20 MG, IBI311, lonigutamab, Satralizumab, TEPEZZA, LASN01, CFZ533, linsitinib, LASN01, and others
Stay ahead in the Graves Ophthalmopathy Therapeutics Market with DelveInsight’s Strategic Report @ Graves Ophthalmopathy Market Outlook
Graves Ophthalmopathy Epidemiology Segmentation in the 7MM
- Prevalent Cases
- Diagnosed Prevalent Cases
- Gender-specific Diagnosed Prevalent Cases
- Moderate-to-severe Drug-treated Cases of Acute Graves Ophthalmopathy in the 7MM
- Acute Diagnosed Prevalent Cases
- Diagnosed Prevalent Cases of Graves Ophthalmopathy by Chronicity in the 7MM
Download the report to understand which factors are driving Graves Ophthalmopathy epidemiology trends @ Graves Ophthalmopathy Prevalence
Marketed Graves’ ophthalmopathy Therapies
- TEPEZZA (teprotumumab): Horizon Therapeutics/ Amgen
Teprotumumab, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), is a fully human IgG1 monoclonal antibody produced in Chinese hamster ovary (CHO-DG44) cells with a molecular weight of approximately 148 KD. The metabolism of teprotumumab has not been fully characterized; however, it is expected to undergo metabolism via proteolysis. TEPEZZA for injection is supplied as a sterile, preservative-free, and white to off-white, lyophilized powder for IV infusions.
Emerging Graves’ ophthalmopathy Therapies
- Batoclimab (IMVT 1401): Immunovant Sciences
Immunovant’s first investigational product, batoclimab (IMVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). In nonclinical studies and clinical trials, batoclimab has been observed to reduce IgG antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases, and, as a result, this product candidate has the potential to address a variety of IgG-mediated autoimmune diseases as a self-administered SC injection.
- VRDN-001: Viridian Therapeutics
Viridian’s lead product candidate, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of Graves’ Ophthalmopathy. In preclinical studies, VRDN-001 had shown to be a full antagonist of IGF-1R, with complete receptor blockade than other anti-IGF-1R antibodies, including the only approved Graves’ Ophthalmopathy therapy.
Get In-Depth Knowledge on Graves Ophthalmopathy Market Trends and Forecasts with DelveInsight @ Graves Ophthalmopathy Treatment Market
Graves’ Ophthalmopathy Treatment Market
Graves’ ophthalmopathy is an autoimmune inflammatory disorder associated with thyroid disease, which affects ocular and orbital tissues. It is also known as Graves’ orbitopathy, Graves’ eye disease, thyroid eye disease (TED), and thyroid-associated ophthalmopathy. It is the main extrathyroidal manifestation of Graves’ disease (GD) and is often disfiguring, significantly impairing the QoL of affected individuals and causing great indirect and direct costs to health systems.
Graves Ophthalmopathy Market Outlook
Nearly 50% of patients with Graves’ Disease report symptoms of Graves’ Ophthalmopathy, which are generally mild. The Graves’ Ophthalmopathy diagnosis is typically made clinically based on presenting ocular symptoms and signs. Timely diagnosis permits appropriate evaluation and treatment and might prevent the progression to more severe disease manifestations. The two most common signs of Graves’ Ophthalmopathy are upper eyelid retraction (around 90% of patients) and proptosis.
Unlock Strategic Insights with DelveInsight’s Comprehensive Graves Ophthalmopathy Market Report @ Graves Ophthalmopathy Market Drivers and Barriers
Scope of the Graves Ophthalmopathy Market Report
- Coverage 7MM
- Graves Ophthalmopathy Companies- Immunovant Sciences, Novartis, Viridian Therapeutics, and others.
- Graves Ophthalmopathy Therapies- Batoclimab (IMVT 1401), RVT-1401, Teprotumumab, VRDN-001 10 mg/kg Drug, TOUR006 - 20 MG, IBI311, lonigutamab, Satralizumab, TEPEZZA, LASN01, CFZ533, linsitinib, LASN01, and others.
- Graves Ophthalmopathy Therapeutic Assessment: Graves Ophthalmopathy Current marketed and Graves Ophthalmopathy Emerging Therapies
- Graves Ophthalmopathy Market Dynamics: Graves Ophthalmopathy Market drivers and Graves Ophthalmopathy Market Barriers
Table of Content
1 Key Insights
2 Report Introduction
3 Graves’ Ophthalmopathy Market Overview at a Glance
4 Executive Summary of Graves’ Ophthalmopathy
5 Graves’ ophthalmopathy Epidemiology and Market Methodology
6 Disease Background and Overview
7 Epidemiology and Patient Population
8 Patient Journey
9 Key Endpoints in Graves’ Ophthalmopathy Clinical Trials
10 Marketed Therapies
11 Emerging Therapies
12 Graves’ Ophthalmopathy: The 7MM Analysis
13 Graves’ Ophthalmopathy Market Access and Reimbursement
15 Graves’ Ophthalmopathy SWOT Analysis
16 Graves’ Ophthalmopathy Unmet Needs
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage
